Baseline characteristics of patients treated with teclistamab combined with IVIG supplementation, or without IVIG supplementation
| . | IVIG as primary prophylaxis, n = 20 . | No IVIG (IVIG only after serious infection), n = 32 . | ||
|---|---|---|---|---|
| Age (y), median (range) | 64 (47 – 80) | 64 (43 – 79) | ||
| Male sex, n (%) | 11 (55) | 18 (56) | ||
| M-protein, n (%) | ||||
| IgG | 12 (60) | 21 (66) | ||
| IgA | 0 | 4 (13) | ||
| IgD | 0 | 1 (3) | ||
| Light chain only | 8 (40) | 6 (19) | ||
| Time (mos) since diagnosis, median (range) | 89 (23 – 211) | 72 (15 – 281) | ||
| Duration (mos) of follow-up since start of teclistamab, median (range) | 5 (1 – 31) | 5 (0.8 – 51) | ||
| Number of prior lines of treatment, median (range) | 5 (2 – 11) | 6 (2 – 14) | ||
| Prior stem cell transplantation, n (%) | ||||
| Autologous SCT | 14 (70) | 27 (84) | ||
| Allogeneic SCT | 2 (10) | 5 (16) | ||
| Refractory disease, n (%) | ||||
| IMiD refractory | 19 (95) | 31 (97) | ||
| PI refractory | 15 (75) | 26 (81) | ||
| CD38-targeting antibody refractory | 20 (100) | 30 (94) | ||
| Triple-class refractory∗ | 14 (70) | 23 (72) | ||
| Penta-drug refractory† | 3 (15) | 10 (31) | ||
| Prior IMiD treatment, n (%) | Exposed | Refractory‡ | Exposed | Refractory‡ |
| Thalidomide | 12 (60) | 2 (10) | 13 (41) | 5 (16) |
| Lenalidomide | 19 (95) | 18 (90) | 31 (97) | 30 (94) |
| Pomalidomide | 14 (70) | 14 (70) | 24 (75) | 24 (75) |
| Iberdomide | 4 (20) | 4 (20) | 11 (34) | 11 (34) |
| Prior PI treatment, n (%) | Exposed | Refractory‡ | Exposed | Refractory‡ |
| Bortezomib | 16 (80) | 12 (60) | 31 (97) | 21 (66) |
| Carfilzomib | 11 (55) | 4 (20) | 22 (69) | 17 (53) |
| Ixazomib | 3 (15) | 3 (15) | 1 (3) | 1 (3) |
| Prior CD38-targeting antibody treatment, n (%) | Exposed | Refractory‡ | Exposed | Refractory‡ |
| Daratumumab | 20 (100) | 20 (100) | 29 (91) | 29 (91) |
| Isatuximab | 0 | 0 | 1 (3) | 1 (3) |
| Prior bispecific antibody treatment, n (%) | Exposed | Refractory‡ | Exposed | Refractory‡ |
| Teclistamab (BCMAxCD3) | 0 | 0 | 0 | 0 |
| Talquetamab (GPRC5dxCD3) | 1 (5) | 1 (5) | 3 (9) | 3 (9) |
| Other prior myeloma treatment, n (%) | Exposed | Refractory‡ | Exposed | Refractory‡ |
| Elotuzumab | 2 (10) | 2 (10) | 3 (9) | 3 (9) |
| Durvalumab | 1 (5) | 1 (5) | 3 (9) | 3 (9) |
| Nivolumab | 2 (10) | 2 (10) | 4 (13) | 3 (9) |
| . | IVIG as primary prophylaxis, n = 20 . | No IVIG (IVIG only after serious infection), n = 32 . | ||
|---|---|---|---|---|
| Age (y), median (range) | 64 (47 – 80) | 64 (43 – 79) | ||
| Male sex, n (%) | 11 (55) | 18 (56) | ||
| M-protein, n (%) | ||||
| IgG | 12 (60) | 21 (66) | ||
| IgA | 0 | 4 (13) | ||
| IgD | 0 | 1 (3) | ||
| Light chain only | 8 (40) | 6 (19) | ||
| Time (mos) since diagnosis, median (range) | 89 (23 – 211) | 72 (15 – 281) | ||
| Duration (mos) of follow-up since start of teclistamab, median (range) | 5 (1 – 31) | 5 (0.8 – 51) | ||
| Number of prior lines of treatment, median (range) | 5 (2 – 11) | 6 (2 – 14) | ||
| Prior stem cell transplantation, n (%) | ||||
| Autologous SCT | 14 (70) | 27 (84) | ||
| Allogeneic SCT | 2 (10) | 5 (16) | ||
| Refractory disease, n (%) | ||||
| IMiD refractory | 19 (95) | 31 (97) | ||
| PI refractory | 15 (75) | 26 (81) | ||
| CD38-targeting antibody refractory | 20 (100) | 30 (94) | ||
| Triple-class refractory∗ | 14 (70) | 23 (72) | ||
| Penta-drug refractory† | 3 (15) | 10 (31) | ||
| Prior IMiD treatment, n (%) | Exposed | Refractory‡ | Exposed | Refractory‡ |
| Thalidomide | 12 (60) | 2 (10) | 13 (41) | 5 (16) |
| Lenalidomide | 19 (95) | 18 (90) | 31 (97) | 30 (94) |
| Pomalidomide | 14 (70) | 14 (70) | 24 (75) | 24 (75) |
| Iberdomide | 4 (20) | 4 (20) | 11 (34) | 11 (34) |
| Prior PI treatment, n (%) | Exposed | Refractory‡ | Exposed | Refractory‡ |
| Bortezomib | 16 (80) | 12 (60) | 31 (97) | 21 (66) |
| Carfilzomib | 11 (55) | 4 (20) | 22 (69) | 17 (53) |
| Ixazomib | 3 (15) | 3 (15) | 1 (3) | 1 (3) |
| Prior CD38-targeting antibody treatment, n (%) | Exposed | Refractory‡ | Exposed | Refractory‡ |
| Daratumumab | 20 (100) | 20 (100) | 29 (91) | 29 (91) |
| Isatuximab | 0 | 0 | 1 (3) | 1 (3) |
| Prior bispecific antibody treatment, n (%) | Exposed | Refractory‡ | Exposed | Refractory‡ |
| Teclistamab (BCMAxCD3) | 0 | 0 | 0 | 0 |
| Talquetamab (GPRC5dxCD3) | 1 (5) | 1 (5) | 3 (9) | 3 (9) |
| Other prior myeloma treatment, n (%) | Exposed | Refractory‡ | Exposed | Refractory‡ |
| Elotuzumab | 2 (10) | 2 (10) | 3 (9) | 3 (9) |
| Durvalumab | 1 (5) | 1 (5) | 3 (9) | 3 (9) |
| Nivolumab | 2 (10) | 2 (10) | 4 (13) | 3 (9) |
GPRC5D, G protein–coupled receptor family C group 5 member D; IMiD, immunomodulatory drug; PI, proteasome inhibitor; SCT, stem cell transplantation.
triple-class refractory means refractory to an IMiD, a PI, and a CD38-targeting antibody;
penta-drug refractory means refractory to lenalidomide, pomalidomide, bortezomib, carfilzomib, and a CD38-targeting antibody;
refractory disease is defined as progressive disease during therapy, no response (less than PR), or progressive disease within 60 days of stopping treatment, according to the International Uniform Response Criteria for Multiple Myeloma.